Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Sezary Syndrome 2Recurrence 2Neoplasms 2Mycosis Fungoides 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Soft Tissue Neoplasms 1Sarcoma 1Respiratory Distress Syndrome 1Radiation Pneumonitis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1

Interventions

tocilizumab 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Respiratory Distress Syndrome × Disulfides × Clear all
NCT04370834 2025-02-04

Tocilizumab for Patients With Cancer and COVID-19 Disease

National Cancer Institute (NCI)

Phase 2 Terminated
1 enrolled 10 charts
Other hematologic neoplasm

Pneumonia, Respiratory Distress Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡